BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Arrowhead Pharmaceuticals (ARWR)Arrowhead Pharmaceuticals2026-06-25 13:46 ESTCompany update

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the

Open original release

Related news

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

ARWRArrowhead Pharmaceuticals2026-06-25 13:46 EST

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

View all latest news

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ARWRArrowhead Pharmaceuticals2026-06-26 07:29 EST

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

ARWRArrowhead Pharmaceuticals2026-06-26 07:29 EST

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

ARWRArrowhead Pharmaceuticals2026-06-26 07:29 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

ARWRArrowhead Pharmaceuticals2026-06-26 07:29 EST

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

ARWRArrowhead Pharmaceuticals2026-06-26 07:29 EST

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States